	Zahlungsmittel Und Äquivalente		Datum
AbbVie	USD 5.63B	838M	2025-09
Acadia Pharmaceuticals	USD 847.02M	85.02M	2025-09
Agios Pharmaceuticals	USD 89.13M	3.58M	2025-12
ALKERMES	USD 616.45M	95.25M	2025-09
Alnylam Pharmaceuticals	USD 1.66B	167M	2025-12
Amgen	USD 9.13B	316M	2025-12
Biogen	USD 3.01B	854.3M	2025-12
BioMarin Pharmaceutical	USD 1.25B	36.29M	2025-09
Cytokinetics	USD 225.47M	150.53M	2025-09
Enanta Pharmaceuticals	USD 37.44M	5.14M	2025-12
Exelixis	USD 482.49M	106.19M	2025-12
Gilead Sciences	USD 7.33B	2.19B	2025-09
Halozyme Therapeutics	USD 419.66M	357.8M	2025-09
Incyte	USD 3.58B	650.78M	2025-12
Ionis Pharmaceuticals	USD 2.24B	1.94B	2025-09
Nektar Therapeutics	USD 41.03M	1.96M	2025-09
Neurocrine Biosciences	USD 713M	372.8M	2025-12
Pfizer	USD 1.34B	295M	2025-09
Prothena	USD 330.84M	40.6M	2025-09
Regeneron Pharmaceuticals	USD 18.87B	16.36B	2025-12
Repligen	USD 748.75M	39.89M	2025-09
Rigel Pharmaceuticals	USD 48.53M	4.87M	2025-09
Sarepta Therapeutics	USD 613.08M	102.48M	2025-09
Teva Pharmaceutical Industries	USD 3.56B	1.35B	2025-12
Ultragenyx Pharmaceutical	USD 202.51M	36.4M	2025-09
Vertex Pharmaceuticals	USD 6.61B	321.1M	2025-12
Xoma	USD 143.9M	7.68M	2024-06

Neurocrine Biosciences Zahlungsmittel Und Äquivalente - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.